Taco van Welzenis represented OIFE at the videoconference in the MEDEV-MOCA-meeting which took place on May 26th. The setrusumab project of Mereo Biopharma was the topic (Mereo Biopharma). BPS-804 (setrusumab) is a fully human monoclonal antibody designed to inhibit sclerostin, thereby improving bone strength and therefore reduce fractures in patients with OI. It has been tested in adults with OI, and a bigger trial to test the drug in children in a number of countries is in the planning phase.

MoCA provides a mechanism for European countries to collaborate on coordinated access to orphan medicines in a voluntary, dialogue-based approach, intended to create a fluid set of interactions between key stakeholders, across all aspects of a product.

MEDEV stands for Medicine Evaluation Committee and represents an informal cooperation between 22 national authorities from 18 Member States and Switzerland responsible for the assessment, pricing and reimbursement of medicines in Europe. MEDEV members include national HTA agencies and social health insurers (payers).